# Ginsenosides as Potential Natural Ligands of SLC3A2: Computational Insights in Cancer

## TL;DR

This study explores how ginsenosides from ginseng may bind to SLC3A2, a protein linked to cancer, using computational methods to suggest their potential as natural anti-cancer agents.

## Contribution

The study identifies ginsenosides as novel potential natural ligands for SLC3A2 through computational modeling.

## Key findings

- Ginsenosides Km, Ro, CK, Rk1, and Ra1 showed high binding affinities to SLC3A2 with energies between −7.7 and −9.3 kcal/mol.
- Molecular dynamics simulations confirmed the stability and dynamic behavior of these ginsenosides when bound to SLC3A2.
- The findings suggest ginsenosides could be promising candidates for anti-cancer therapies targeting SLC family proteins.

## Abstract

Panax ginseng has been used as a traditional Oriental medicinal herb. This research investigates the potential of ginsenosides, bioactive phyto compounds derived from ginseng, as ligands of the solute carrier (SLC) family, including SLC3A2, SLC7A6, SLC7A11, SLC7A5, SLC7A8, SLC43A1, LCN2, SLC7A9, SLC7A7, and SLC7A10 proteins—which are overexpressed in various cancers and linked to metastasis. Using molecular docking (MD), ginsenosides (Km, Ro, compound K (CK), Rk1, and Ra1) with high binding affinities to SLC3A2 were identified, exhibiting binding energies of −9.3, −9.1, −8.7, −8.0, and −7.7 kcal/mol, respectively. Further molecular dynamics simulations (MDSs) conducted using GROMACS revealed improved stability, flexibility, and dynamic behavior of the selected ginsenosides, predicting their potential as natural ligands to bind with SLC3A2. Though this computational prediction underscores these ginsenosides as promising candidates as natural ligands to bind and interact with SLC family proteins during anti-cancer therapies, further in vitro and in vivo studies are needed to validate these interactions and anti-cancer effects.